VISCOSUPPLEMENTATION MARKET ANALYSIS

Viscosupplementation Market Size and Trends

The viscosupplementation market is estimated to be valued at USD 3.84 Bn in 2024 and is expected to reach USD 6.49 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.

To learn more about this report, Request sample copy

The viscosupplementation market is expected to witness positive growth over the forecast period. This is primarily due to the rising geriatric population who are more prone to osteoarthritis coupled with the growing prevalence of obesity. Furthermore, the market is expected to benefit from the introduction of novel hyaluronic acid-based viscosupplementation products with improved efficacy and reduced number of injections required.

Growing elderly population and risk of osteoarthritis

As the global population is aging significantly, the number of elderly people prone to mobility issues and joint disorders is increasing rapidly. Osteoarthritis is one of the most common causes of disability among the geriatric population worldwide. It usually occurs in the hands, hips, and knees and can make even basic movements extremely painful. As people are living longer due to improvements in healthcare and nutritional standards, osteoarthritis has become highly prevalent. The rising population of older individuals fuels the demand for effective pain management and treatment options for osteoarthritis. Viscosupplementation therapies provide lubrication and protection to joints affected by osteoarthritis, helping maintain movement and reducing discomfort. They allow many elderly patients to avoid joint replacement surgeries or other invasive procedures, improving their quality of life.

To learn more about this report, Request sample copy

Widespread information availability through online health resources and support groups has raised awareness about various non-surgical alternatives for osteoarthritis. Several patients now prefer conservative treatment approaches over joint replacement surgeries, at least in the initial stages of the disease. Viscosupplementation therapies are very attractive in this context since they are non-invasive and involve simple local injections to supplement joint fluid viscosity. Compared to joint replacement, which is often a last resort, viscosupplementation allows patients to avoid complex surgery and a long recovery period. It preserves the natural joint and improves mobility without major downtime or risks of surgery.